

## Pulmonary Arterial Hypertension (PAH) Agents

Please fax this completed form to (866) 399-0929 OR mail to: Envolve Pharmacy Solutions PA Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720.

Date of request:	Reference #:	MAS:	
Patient	Date of birth	ProviderOne ID or Coordinated Care ID	
Pharmacy name	Pharmacy NPI	Telephone number	Fax number
Prescriber	Prescriber NPI	Telephone number	Fax number
Medication and strength		Directions for use	Qty/Days supply
<p>1. Is this request for a continuation of existing therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No          If yes, is there documentation supporting disease stability <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>2. Indicate the diagnosis:</p> <p><input type="checkbox"/> Pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group 1 and</p> <p style="margin-left: 20px;"><input type="checkbox"/> WHO Functional class II symptoms</p> <p style="margin-left: 20px;"><input type="checkbox"/> WHO Functional class III symptoms</p> <p style="margin-left: 20px;"><input type="checkbox"/> WHO Functional class IV symptoms</p> <p><input type="checkbox"/> Persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO group 3 or 4)</p> <p><input type="checkbox"/> Other. Specify _____</p> <p>3. Has the patient tried a calcium channel blocker? <input type="checkbox"/> Yes <input type="checkbox"/> No          If not, was it due to one of the following:</p> <p style="margin-left: 20px;"><input type="checkbox"/> A contraindication to a calcium channel blocker</p> <p style="margin-left: 20px;"><input type="checkbox"/> Patient had a negative response to acute vasoreactivity test (AVT).</p> <p style="margin-left: 20px;"><input type="checkbox"/> Acute vasoreactivity test not indicated for the patient.</p> <p style="margin-left: 20px;"><input type="checkbox"/> Acute vasoreactivity test is contraindicated (SBP &lt; 90 mmHg; cardiac index &lt; 2 L/min/m<sup>2</sup>, or PH functional class IV)</p> <p style="margin-left: 20px;"><input type="checkbox"/> Other. Explain _____</p> <p>4. Will the requested therapy be used in combination with any of the following (check all that apply)?</p> <p><input type="checkbox"/> Combination of phosphodiesterase inhibitor and soluble guanylate cyclase stimulator</p> <p><input type="checkbox"/> Combination of selexipag and parenteral prostanoid</p> <p><input type="checkbox"/> None of the above</p> <p>5. <b>For Selexipag:</b> Does the patient have a history of failure, contraindication, or intolerance to an endothelin receptor antagonist? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>6. Is this prescribed by or in consultation with a specialist in one of the following:</p> <p><input type="checkbox"/> Cardiology <input type="checkbox"/> Pulmonology <input type="checkbox"/> Other. Specify _____</p>			
<b>CHART NOTES ARE REQUIRED WITH THIS REQUEST</b>			
Prescriber signature	Prescriber specialty	Date	

Envolve Pharmacy Solutions will respond via fax or phone within 24 hours of receipt of the request. Requests for prior authorization must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)